Lebrikizumab

Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases[1][2][3].

Product Specifications

CAS Number

[953400-68-5]

Product Name Alternative

TNX-650; MILR1444A; RG3637

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/lebrikizumab.html

Purity

99.90

Solubility

H2O

Smiles

[Lebrikizumab]

Molecular Weight

(145.318 kDa)

References & Citations

[1]Jonathan Corren, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22;365 (12) :1088-98.|[2]Loh TY, et al. Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis. J Asthma Allergy. 2020 Feb 11;13:109-114. |[3]Miron Y, et al. Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2022 Sep;150 (3) :690-700.